The Committee will discuss supplemental new drug application (sNDA) 022496/S 009, for EXPAREL (bupivacaine liposomal injectable suspension) , submitted by Pacira Pharmaceuticals, Inc., to produce local analgesia and as a nerve block to produce regional analgesia.
Back to All Events
Earlier Event: February 9
Advisory Committee on Heritable Disorders in Newborns and Children
Later Event: February 16
Cancelled: Psychopharmacologic Drugs Advisory Committee